Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. The company's website is located at www.telomirpharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Telomir Pharmaceuticals, Inc. does
In the company’s own words
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. The company's website is located at www.telomirpharma.com.
The company's lead investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance, particularly iron, copper, calcium, and zinc, through a regulated exchange mechanism. Telomir-1 operates through multiple biological pathways including modulation of oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. The company has not yet conducted human clinical trials but has completed multiple preclinical studies demonstrating favorable safety profiles and biological activity across various disease models.
Telomir-1 is under investigation for therapeutic potential across multiple disease areas including Wilson's disease, Type 2 diabetes, age-related macular degeneration, oncology, Progeria, and general aging-related conditions. Preclinical studies have demonstrated dose-dependent efficacy in normalizing blood glucose and reducing insulin levels in diabetes models, preservation of telomere integrity and longevity improvements in aging models, and anti-tumor activity in various cancer xenografts. The company completed IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies, with Telomir-1 reported to be well tolerated without treatment-related adverse or dose-limiting toxicities.
The company targets submission of an Investigational New Drug application to the FDA in 2026, with plans to initiate Phase 1/2 clinical trials thereafter, subject to regulatory approval and resource availability. Telomir-1 is licensed from MIRALOGX, LLC, a related party intellectual property company, under an exclusive perpetual license covering U.S. rights for human and veterinary applications. The company is currently an early-stage development entity with no revenues and substantial liquidity needs. The company is also pursuing a merger with TELI Pharmaceuticals, Inc., which would align U.S. and non-U.S. rights to Telomir-1 within a single public company structure.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- MIAMI, FL
- Fiscal year end
- December
- CIK
- 1971532
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Telomir Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Telomir Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Telomir Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Telomir Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Telomir Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”